Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
effervescent ibuprofen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| effervescent ibuprofen tablets | DRUG | - |
| effervescent Aspirin plus Vitamin C tablets | DRUG | - |
| ibuprofen tablets | DRUG | - |
| placebo | DRUG | - |
Inclusion: * Moderate or severe post-operative pain following surgical extraction of two or more third molars, at least one of which must be a partial or complete bony mandibular impaction * In general good health with no contraindications to the study medication or rescue medication (tramadol or a...
Effervescent ibuprofen is used for the treatment of pain, specifically post-surgical dental pain. It is a small molecule drug being developed by Pfizer, Inc. (PFE). The drug is currently in Phase 3 clinical development and is considered investigational, meaning it has not yet been approved by regulatory authorities.
Effervescent ibuprofen is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for the treatment of pain, specifically post-surgical dental pain.
Effervescent ibuprofen is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval. The drug is being studied for the treatment of pain, specifically post-surgical dental pain, and is being developed by Pfizer, Inc. (PFE).
Effervescent ibuprofen has one completed Phase 3 clinical trial, identified by the National Clinical Trial number NCT00631111. The trial, titled 'Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain,' enrolled 270 participants in the United States. The study was randomized, double-blind, and placebo-controlled.
Effervescent ibuprofen is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The drug is being studied for the treatment of post-surgical dental pain, and its safety and efficacy have not yet been established for regulatory approval. It is being developed by Pfizer, Inc. (PFE).